Values of the Immune Activation Markers CD38 and HLA-DR and the Ratio CD4/CD8 According to the Delay of Combined AntiRetroviral Therapy (c-ART) Initiation in Primary HIV-infected Patients (PRIMIMMUNO)
Completed
- Conditions
- HIV-infected Patients
- Interventions
- Biological: lymphocytes immunophenotyping
- Registration Number
- NCT02827227
- Lead Sponsor
- Hospices Civils de Lyon
- Brief Summary
The objective was to identify factors associated with the normalization of the CD4/CD8 ratio (\>=1) in patients with a history of primary HIV infection (PHI) and long-term combined antiretroviral therapy (cART).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 99
Inclusion Criteria
all HIV patients with a known history of PHI and a minimum of 2 years of effective cART (< 200 copies/mL) without interruption or virological failure
Read More
Exclusion Criteria
Patients with hepatitis C or B virus co-infection or with a history of neoplasia or immunosuppressive therapy after the date of PIH
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Primary HIV- Infected patients lymphocytes immunophenotyping Primary HIV- Infected patients with a minimum of 2 years of effective cART.
- Primary Outcome Measures
Name Time Method percentage of CD4+ and CD8+ T lymphocytes with activation markers (CD38 + and HLA-DR) Day 0 percentage of CD4+ and CD8+ T lymphocytes with activation markers (CD38 + and HLA-DR) according to the delay of cART initiation (early 3 months or delayed \> 3 months).
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Hospices Civils de Lyon / Hôpital de la Croix Rousse
🇫🇷Lyon, France